Replies to post #3370 on The Sub Penny Bull Pen

[Abondanceinvest]

Gm Frogger, BISU news and move coming>>>DD>>
Bio-solutions Corp. (BISU)
0.0155 ? 0.0005 (3.33%)
Volume: 830,700 @ 3:44:28 PM ET
Bid Ask Day's Range
0.0155 0.018

BISU 0.025-0.03.news soon Under_0.10_big_buyers_DD_MUST_READ>
Bio-Solutions Corp. has launched the new product - Type2 Defense™ - to tap into the rapidly growing demand for diabetic and functional supplementation. Type2 Defense™ will soon be sold on the company’s website www.type2defense.com (currently under development).

http://www.nutricaplabs.com/ ( fortune500 ) agreement$$

Abondanceinve$t



BISU IN A MULTI BILLION-DOLLAR_MARKET-AND_LOOKING_AT ANOTHER
http://www.biosolutionscorp.com/blog/bisu-in-a-multi-billion-dollar-market-and-looking-at-another/


BISU NATURAL REMEDIES LIKE MEDICAL MARIJUANA CAN IMPACT DIABETES

http://www.biosolutionscorp.com/blog/natural-remedies-like-medical-marijuana-can-impact-diabetes/

NATURAL REMEDIES LIKE MEDICAL MARIJUANA CAN IMPACT DIABETES

As everyone knows, we are almost ready to role out our Type 2 Defense product. Production is underway and we expect to have it on shelves very soon. Our distribution contacts assure us that the product will be well received. We expect that follow up products should be available for roll out in Q3. The market for natural remedies is our focus and the branding of our efforts should lead to our company being recognized as a market leader.
Our commitment to becoming “The Natural Remedy Company” has led us to consider other opportunities to grow our product offerings. The field of medical marijuana is of interest to our team. This hot button issue appears to be topical at a regional and national level. We have open the door to some potential acqusitions in the sector and we anticipate that we will have the opportunity to update the market in short order. Medical marijuana has some beneficial aspect to treating all kinds of diseases and emdical conditions, includng diabetes. The link below is very interesting and shows clearly that the medical marijuana field is something to seriously consider for our company.
http://www.dlife.com/diabetes/lifestyle/theresa_garnero/marijuana
This is a a great time to be a shareholder of Bio-Solutions. We are positioned to fasttrack the company’s product positioning and roll out as well as concluding some accreative acquisitions.


BISU.MEDICAL MARIJUANA COULD BE THE_PATH_TO_WELLNESS_AND_PROSPERITY
http://www.biosolutionscorp.com/blog/medical-marijuana-could-be-the-path-to-wellness-and-prosperity/

MEDICAL MARIJUANA COULD BE THE PATH TO WELLNESS AND PROSPERITY

Our company entered the natural remedy field with our initial product offering to help diabetes patients deal with their condition. We have big plans for the roll out including endorsement deals with NFL and NHL athletes. These endorsement deals are in the advanced discussion stage and we anticipate being in a position to release news on these undertakings before month end. This product is at the core of our company’s mission to build our reputation as a Natural Remedy Company.
Searching for new opportunities is a lynchpin to our growth strategy. We have ben watching the whole medical marijuana debate with keen interest. Our group is interested in the sector because of the natural remedy component.
http://www.bottomlinepublications.com/content/article/natural-remedies/medical-marijuana
The addition of a medical marijuana project to our product portfolio could propel growth and put the company in an enviable position by being immediately accretive. A series of projects are under consideration and we will release news as soon as a final decision is made by management. This is an important decision given the potential positive impact in terms of building value for our shareholders. Companies like Medbox Inc. (http://www.thedispensingsolution.com/) and Medical Marijuana Inc. (http://www.medicalmarijuanainc.com/) have been trailblazers in the space and in the process they have created enormous wealth for investors. We think we could do the same by chosing the right project.


BISU THIS YEAR WILL BE A LANDMARK_YEAR_FOR_TYPE_2_DEFENSE_READ!!
http://www.biosolutionscorp.com/blog/this-year-will-be-a-landmark-year-for-type-2-defense/


THIS YEAR WILL BE A LANDMARK YEAR FOR TYPE 2 DEFENSE

We are very excited to enter this new year with high hopes and expectations. The company has gone through intensive periods of startegic planning and we are confident that we are well positioned to deliver on the core product line for Bio-Solutions Corp. As shareholders know, we are preparing to market Type 2 Defense and it is our belief that the marketplace will be very receptive to the the superior formulation of this unique product in the diabetes space.
Americans are suffering from diabetes in growing numbers, The demographics point to a 100% + increase in cases to almost 30 million by 2050. This huge jump in cases bodes well for our product and the sales should reflect that this year and in years to come. Our expectation for Type 2 Defense are very high and the management team will be working hard to make sure that shareholders share in the rewards of a product has all the earmarks of a winner.
Bio-Solutions plans for Type 2 Defense include athlete endorsements, regional and countrywide distribution and media events (US and Canada). Our time is now and we are confident that we will take the opportunity to have a solid product launch and follow through. Management has established relationships with outside marketing help that has successfully marketed these type of products in the past. This will be a very interesting time to be a shareholder. We will work hard to deliver value and results and turn the share price around to more normalized levels. If you have any questions, please do not hesitate to contact us.
Related articles




BISU chart$ NFL johnson is sensitive to the_cause_of_diabetes.read

Johnson comes from the top program in the nation with a culture of winning and stout defense. He has no off-field issues to note.

Johnson ran into tragedy when his 49-year-old mother, Maime, passed away from complications of diabetes. The entire team went to the funeral three hours away, showing the kind of respect and care his fellow players have for him.

http://bleacherreport.com/articles/1598137-nico-johnson-scouting-report-nfl-outlook-for-alabama-ilb

http://www.biosolutionscorp.com/blog/nico-johnson-scouting-report-nfl-outlook-for-alabama-ilb/


http://www.biosolutionscorp.com/products/

BISU

baseball.. Sosa alos...is sensitive to the_cause_of_diabetes


BISU Sammy Sosa-MEET KENDALL SIMMONS_Jay_Cutler..and more

athlete endorsements for the product by players in the NHL, NFL, NBA and MLB news soon!! bisu blog-twitter-website nice info..

Sammy Sosa Would like to talk to you about endorsing our product @ http://www.biosolutionscorp.com/products

https://twitter.com/TheRealMr609

@TheRealMr609
I am the real Sammy Sosa. I will always love baseball, but now I'm a businessman and entrepreneur.

TheRealMr609 Would like to talk to you about endorsing our product @ http://www.biosolutionscorp.com/products/.We have NHL and NFL players and need MLB players.

https://twitter.com/bisuotcbb

news will be interesting soon

Abondanceinvest


MEET KENDALL SIMMONS
Living with diabetes is not easy. Daily care is required to allow you to live a full and complete life. Diabetes is not a brick wall but merely a small detour when it comes to reaching your life’s goals. Proper attention to preventive nutrition and a selection of natural remedies can help any diabetes sufferer lead a normal and even extraordinary life. Professional athletes with diabetes are a great example of overcoming the diabetes hurdle and taking your body optimal physical performance. The world of sports has some extraordinary stories of athletes who excelled despite having been diagnosed with type 1 and type 2 diabetes. There is no sport like football and no league like the NFL. In this blog installment we will look at some NFL superstars who didn’t let diabetes stand in the way of success.

We will kick off our short list with Kendall Simmons. Kendall was a star for the Pittsburgh Steelers for a number of years. While he was playing, he had to deal with his diabetes condition on a daily basis. Anyone who knows the Steelers, know they are a top notch organization with a track record of excellence. The fact that Kendall could be starter for the team on a daily basis should be an inspiration to anyone with diabetes. Football is about as tough a game as you get but with proper care and attention to your diabetes, you can go toe to toe with people who don’t have your condition. Not only did Kendall go toe to toe with the best, he was part of two Super Bowl Championshipteams.

Kendall Simmons success is not a one off. Consider the case of Mike Sinclair. Mike was a 3 time Pro Bowl player for the Philadelphia Eagles despite having to deal with diabetes. He was a mega star in the NFL and led the league in sacks with 16 1/2 in 1998. Following his playing days, Mike went on to many successful coaching stints. He didn’t let diabetes stop him while playing and he continued to contribute even after retirement.

For those readers who missed Kendall and Mike in their glory days, you can catch current NFL stars who have diabetes in their lives. The most notable example of a current NFL player with diabetes is Jay Cutler. The Chicago Bears star QB is well known to fans of the game from coast to coast but most people have no idea that he has diabetes. Jay has been at the helm for some very big Bears victories and should be a role model for diabetes sufferers, no matter how old. Jay, just like Kendall and Micheal, manages his diet and uses preventive measures to insure that diabetes doesn’t become a bigger issue than it has to be.



http://www.biosolutionscorp.com/blog/meet-kendall-simmons/





http://www.dlife.com/diabetes/famous_people/sports/jay-cutler-biography




Jay Cutler Biography

Claim to Fame: Football Player
DOB: April 29, 1983
Diabetes Type: 1

Jay Cutler was born on April 29, 1983 in Santa Claus, Indiana. He attended Heritage Hill High School in Lincoln City, Indiana where he started as quarterback for the football team 3 out of the 4 years he was there. During his junior and senior seasons, he led his team to a 26-1 record. It was in Cutler’s final year at Heritage Hill that his team played a perfect season with a 15-0 record, and proceeded to take the school’s first championship in an overtime win over Zionsville. Cutler and his fellow teammates outscored opponents 746-85, including a 90-0 route against Pike Central.

Along with his outstanding ability at the quarterback position, Cutler often played safety as well. He intercepted 9 passes his senior year, ranking him twelfth overall in the state of Indiana. He also snagged a first-team All-State selection by the Associated Press in football, a first-team All-State selection in basketball, and an honorable mention All-State selection in baseball.

Following his high school career, Cutler attended Vanderbilt University and started all 45 games as quarterback. In 2002, he set the school record for most touchdowns and most rushing yards by a freshman, earning him first-team freshman All-SEC honors. As a junior he set another school record for completing 61% of his passes, and as a senior in 2005 Cutler soared to an entirely new level. Starting 11 games, he passed for 3,073 yards, 21 touchdowns, and maintained a completion percentage of 59.1. He was the first player at Vanderbilt to win the SEC Offensive Player of the Year since Bob Goodridge in 1967. He was a three-time captain and a four-year starter for the Commodores. He set school records for total offense (9,953 yards), touchdown passes (59), pass yards (8,697), pass completions (710), and pass attempts (1,242). Cutler graduated from Vanderbilt with a bachelor’s degree in human and organizational development in 2005.

Cutler began his career in the National Football League as the 11th pick of the 2006 draft for the Denver Broncos. On July 7, 2006 Cutler and the Broncos signed a 6-year contract worth $48 million ($11 million in bonuses). Then, on December 3, 2006 he made his debut as a professional starting quarterback, unfortunately though the Broncos fell to the Seattle Seahawks 23-20. It was in this game however that Cutler threw one of the longest passes for a debut in NFL history.

On December 17, 2006 he finally tasted victory with a 37-20 win over the Arizona Cardinals. He finished the game with a passing record of 21 completions out of 31 attempts for a total of 261 yards, 2 touchdowns, 1 interception, and quarterback ranking of 101.7 (the highest single-game rating for a rookie since John Elway in 1983). Cutler played in 5 games during his rookie season with the Denver Broncos, and ended it with 1,001 pass yards, 9 touchdowns, and 5 interceptions. In 2007 he saw his first full season but fell short of the playoffs with a 7-9 record.

On May 1, 2008 Jay Cutler revealed that he had been diagnosed with type 1 diabetes and would need daily insulin shots for treatment. Today while fighting to keep his team above .500 in the AFC West, Cutler does volunteer work for mentally challenged young people through Vanderbilt’s “Best Buddies” program, works with the Denver based organization “Dedicated to Diabetes” to improve public knowledge, and in this past offseason he started the “Jay Cutler Foundation” which partnered with Mile High United Way’s “Youth Success Initiative” to help at-risk youth graduate high school.

In April 2009, Cutler returned to his Midwest roots after being traded by the Broncos to the Chicago Bears.


Our team will be solidly implanted in that market with Type 2 Defense and the other products in development. Top line revenue should explode as we roll out professional athlete endorsements for the product by players in the NHL, NFL, NBA and MLB.


BISU invitesshareholders_$HEMP_$MJNA_$MDBX_$CLNP_$SKTO_$FITX_to consider our company and visit our website

LATEST UPDATE http://www.biosolutionscorp.com/

Product on line in May + marijuana news...

[Abondanceinvest]

NEPT-Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2013 Results


2013-05-09 08:00 ET - News Release


LAVAL, Quebec, May 9, 2013 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) will be holding a conference call on Thursday, May 23 at 9:00 am ET to present its results for the fourth quarter and fiscal year ended February 28, 2013. The Company will also be providing an update on the status of its previously disclosed action plan to resume operations and supply customers.

The conference call hosts will be Henri Harland, President & CEO and André Godin, CFO.

To access the conference call within Canada & the U.S., dial toll-free 1-877-380-5664. Outside Canada and the U.S., dial 1-631-813-4882.

Conference call details:

Conference Topic:
Neptune Technologies & Bioressources Fourth Quarter
and Fiscal Year Ended February 28, 2013 Results Call

Conference ID: 70455786

Time: 9:00 AM Eastern Time
Management will accept questions related to the financial results and its operations by telephone during the Q&A period at the end of the presentation. Questions can also be forwarded in advance or during the presentation to [e-mail].

An archived recording of the conference call will be available on Neptune's website (www.neptunebiotech.com) shortly after the call.

Neptune's audited consolidated financial statements for the period ended February 28, 2013 and related MD&A will be made available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on Neptune's website at http://www.neptunebiotech.com prior to the conference call.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids, or PUFAs. Neptune has a patented process of extracting oils from Antarctic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the U.S., European and Asian neutraceutical markets. Neptune's lead products, Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule form and serve as a dietary supplement to consumers.

Through its subsidiaries Acasti Pharma and NeuroBioPharm, in which Neptune respectively holds 57% and 96% of the voting rights, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBio respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti's lead prescription drug candidate is CaPre®, a purified high omega-3 phospholipid concentrate derived from krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking information within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. federal securities laws, both of which we refer to as forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Neptune's current beliefs as well as assumptions made by and information currently available to Neptune and relate to, among other things, Neptune's strategy, strategic goals, research and development activities, research and clinical testing outcome, future operations, future financial position, future revenues/results, projected costs, prospects and plans and objectives of management.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Neptune in its amended and restated annual information form dated September 11, 2012, in its press release announcing an action plan to resume operations and supply customers dated November 26, 2012 and in its other public securities filings available at www.sedar.com and www.sec.gov/edgar.shtml, actual events may differ materially from current expectations. Except as required by law, Neptune disclaims any intention or obligation to update or revise any forward-looking statements.

CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
[e-mail]
www.neptunebiotech.com

Howard Group Contact:
Dave Burwell
+1.888.221.0915
[e-mail]
www.howardgroupinc.com

[Abondanceinvest]

BISU recnt filng 10-Q May 6, 2013 Mar 31, 2013

http://www.otcmarkets.com/stock/BISU/filings